Rejection Requiring Treatment within the First Year following Heart Transplantation: The UNOS Insight
Journal of Personalized Medicine · 29.12.2023 · 14 (1) · 52
DOI: 10.3390/jpm14010052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 29.12.2023. Verfasst von Marco Gemelli und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac, Thoracic, Vascular and Public Health Sciences, University of Padua, 35122 Padova, Italy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1)
Background
Heart failure is an extremely impactful health issue from both a social and quality-of-life point of view and the rate of patients with this condition is destined to rise in the next few years. Transplantation remains the mainstay of treatment for end-stage heart failure, but a shortage of organs represents a significant problem that prolongs time spent on the waiting list. In view of this, the selection of donor and recipient must be extremely meticulous, considering all factors that could predispose to organ failure. One of the main considerations regarding heart transplants is the risk of graft rejection and the need for immunosuppression therapy to mitigate that risk. In this study, we aimed to assess the characteristics of patients who need immunosuppression treatment for rejection within one year of heart transplantation and its impact on mid-term and long-term mortality. (2)
Methods
The United Network for Organ Sharing (UNOS) Registry was queried to identify patients who solely underwent a heart transplant in the US between 2000 and 2021. Patients were divided into two groups according to the need for anti-rejection treatment within one year of heart transplantation. Patients’ characteristics in the two groups were assessed, and 1 year and 10 year mortality rates were compared. (3)
Results
A total of 43,763 patients underwent isolated heart transplantation in the study period, and 9946 (22.7%) needed anti-rejection treatment in the first year. Patients who required treatment for rejection within one year after transplant were more frequently younger (49 ± 14 vs. 52 ± 14 years, p < 0.001), women (31% vs. 23%, p < 0.001), and had a higher CPRA value (14 ± 26 vs. 11 ± 23, p < 0.001). Also, the rate of prior cardiac surgery was more than double in this group (27% vs. 12%, p < 0.001), while prior LVAD (12% vs. 11%, p < 0.001) and IABP (10% vs. 9%, p < 0.01) were more frequent in patients who did not receive anti-rejection treatment in the first year. Finally, pre-transplantation creatinine was significantly higher in patients who did not need treatment for rejection in the first year (1.4 vs. 1.3, p < 0.01). Most patients who did not require anti-rejection treatment underwent heart transplantation during the new allocation era, while less than half of the patients who required treatment underwent transplantation after the new allocation policy implementation (65% vs. 49%, p < 0.001). Patients who needed rejection treatment in the first year had a higher risk of unadjusted 1 year (HR: 2.25; 95% CI: 1.88–2.70; p < 0.001), 5 year (HR: 1.69; 95% CI: 1.60–1.79; p < 0.001), and 10 year (HR: 1.47; 95% CI: 1.41–1.54, p < 0.001) mortality, and this was confirmed at the adjusted analysis at all three time-points. (4)
Conclusions
Medical treatment of acute rejection was associated with significantly increased 1 year mortality compared to patients who did not require anti-rejection therapy. The higher risk of mortality was confirmed at a 10 year follow-up. Further studies and newer follow-up data are required to investigate the role of anti-rejection therapy in the heart transplant population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiac, Thoracic, Vascular and Public Health Sciences, University of Padua, 35122 Padova, Italy.
- Department of Surgery, Lahey Hospital and Medical Center, Burlington, MA 01805, USA.
- Heart and Vascular Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Medical School of Athens, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
- Division of Cardiology, Columbia University Irving Medical Center, New York City, NY 10032, USA.
- Division of Cardiology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
ORCID-Profile: Marco Gemelli, Alvise Guariento, Kyriakos Spiliopoulos, Rabea Asleh, Ernesto Ruiz Duque, Alexandros Briasoulis
Zitieren
APA
Gemelli, M., Doulamis, I. P., Tzani, A., Rempakos, A., Kampaktsis, P., Alvarez, P., Guariento, A., Xanthopoulos, A., Giamouzis, G., Spiliopoulos, K., Asleh, R., Ruiz Duque, E., & Briasoulis, A. (2023). Rejection Requiring Treatment within the First Year following Heart Transplantation: The UNOS Insight. Journal of Personalized Medicine, 14(1), 52. https://doi.org/10.3390/jpm14010052
Vancouver
Gemelli M, Doulamis IP, Tzani A, Rempakos A, Kampaktsis P, Alvarez P, et al. Rejection Requiring Treatment within the First Year following Heart Transplantation: The UNOS Insight. Journal of Personalized Medicine. 2023;14(1):52. doi:10.3390/jpm14010052
BibTeX
@article{Gemelli2023,
author = {Gemelli, Marco and Doulamis, Ilias P and Tzani, Aspasia and Rempakos, Athanasios and Kampaktsis, Polydoros and Alvarez, Paulino and Guariento, Alvise and Xanthopoulos, Andrew and Giamouzis, Grigorios and Spiliopoulos, Kyriakos and Asleh, Rabea and Ruiz Duque, Ernesto and Briasoulis, Alexandros},
title = {Rejection Requiring Treatment within the First Year following Heart Transplantation: The UNOS Insight},
journal = {Journal of Personalized Medicine},
year = {2023},
volume = {14},
number = {1},
pages = {52},
doi = {10.3390/jpm14010052}
}
EUVIMED